Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits

Circulation

Volumn 96, Issue 3, 1997, Pages 916-921

  Friederich, Philip W ^c   Levi, Marcel ^b   Biemond, Bart J ^c   Charlton, Peter ^a   Templeton, David ^a   Van Zonneveld, Anton Jan ^c   Bevan, Paul ^a   Pannekoek, Hans ^c   Ten Cate, Jan W ^c  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NONE

Author keywords

Coagulation; Fibrinolysis; Plasminogen activators; Thrombolysis; Thrombosis

Indexed keywords

6 BENZYLIDENE 3 [5 (2 DIMETHYLAMINOETHYLTHIO) 2 THIENYL]METHYLENE 2,5 PIPERAZINEDIONE; AMINO ACID; FIBRINOGEN; IODINE 125; MONOCLONAL ANTIBODY; PEPTIDE; PIPERAZINEDIONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; XR 5118;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG STRUCTURE; FIBRINOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PLASMA; PRIORITY JOURNAL; RABBIT; THROMBOCYTE; THROMBOSIS; THROMBUS;

ANIMALS; BLOOD PLATELETS; FIBRINOLYSIS; HUMANS; JUGULAR VEINS; MOLECULAR WEIGHT; PIPERAZINES; PLASMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RABBITS; THROMBIN; THROMBOPHLEBITIS;

EID: 0030857519     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Fay WP, Shapiro AD, Shih JL, Schleeff RR, Ginsburg D. Complete deficiency of plasminogen activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992;327:1729-1733.
2. Schleef RR, Higging DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type-1 plasminogen activator inhibitor. J Clin Invest. 1989;83:1747-1752.
3. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EK. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood. 1991;77:528-532.
4. Lee MH, Vosburg H, Anderson K, McDonagh J. Deficiency of plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood. 1993;81:2357-2362.
5. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, de Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene deficient mice, II: effects on hemostasis, thrombosis and thrombolysis. J Clin Invest. 1993;92:2756-2760.
6. Carmeliet P, Collen D. Gene targeting and gene transfer studies on the biological role of the plasminogen/plasmin system. Thromb Haemost. 1995;74:429-436.
7. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor 1 (PAI-1) activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;68:315-320.
8. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental venous and coronary artery thrombosis: effects of systemic administration of an anti-PAI-1 monoclonal antibody. Circulation. 1995;91:1175-1181.
9. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor gene. Nature. 1990;346:74-76.
10. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557-1563.
11. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
12. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis. 1995;9:263-276.
13. Stringer HAR, van Swieten P, Heynen H, Sixma JJ, Pannekoek H. Thrombolysis resistance is largely due to plasminogen activator 1 (PAI-1) released from activated platelets: studies with thrombi generated in the Chandler loop. Arterioscler Thromb. 1994;14: 1452-1458.
14. Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet rich thrombi: the role of PAI-1. Ann N Y Acad Sci. 1992;667:70-80.
15. Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D. Peptide-mediated inactivation of recombinant plasminogen activator-1 in vitro. J Clin Invest. 1995;95: 2416-2420.
16. Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, Machin S, Bevan P. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost. 1996;75:808-815.
17. Barnes CS, Faint RW, Dwyer MC, Critchley DJP, Templeton D, Folkes AJ, Charlton P, Bevan P, Effects of XR5118 on PAI-1 and t-PA activity and arterial thrombus formation in the anaesthesized rat. Br J Pharmacol. 1996;118:97. Abstract.
18. Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP, Pannekoek H. The interaction of plasminogen activator inhibitor 1 (PAI-1) with plasminogen activators (t-PA, u-PA) and fibrin: localization of interaction sites and physiological relevance. Blood. 1991; 78:1254-1261.
19. Jonsson U, Fagerstam L, Lofas S, Stenberg E, Karlsson R, Frostell A, Markey F, Schindler F. Introducing a biosensor based technology for real time biospecific interaction analysis. Ann Biol Clin (Paris). 1993;51:19-26.
20. Ginsberg MH, Taylor L, Painter RG. The mechanism of thrombin-induced platelet factor 4 secretion. Blood. 1980;55:661-670.
21. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984;51:392-395.
22. LeBreton H, Topol E, Plow EF. Evidence for a pivotal role of platelets in vascular reocclusion and restenosis. Cardiovasc Res. 1996;31:235-236.
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
24. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990; 322:33-42.
25. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989; 80:198-205.
26. Yasuda T, Gold HK, Fallon JT, Leinbach RC, Guerrero JL, Scudder LE, Kanke M, Shealy D, Ross MJ, Collen D, Coller BS. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81: 1284-1291.
27. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angiography. N Engl J Med. 1994;94:956-961.
28. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.